[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A: Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol; 2008 Jun;21(6):708-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.
  • Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification for cutaneous lymphomas, is not well characterized.
  • The majority resolved without relapse, one without treatment, four with excision, and four with radiation therapy.
  • One patient developed local recurrence.
  • The patient with multiple lesions had disease progression despite chemotherapy and stem cell transplant.
  • The differential diagnosis includes reactive lymphoid hyperplasia, mycosis fungoides and cutaneous B-cell lymphomas.
  • In patients with isolated cutaneous lesions, the indolent behavior of this rare T-cell neoplasm should be recognized to avoid unnecessary treatment.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311111.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Stavrianeas NG, Katoulis AC, Bozi E, Toumbis-Ioannou E, Kanelleas AI, Makris M, Kalogeromitros D, Panayiotides I: Cutaneous pseudolymphoma following administration of lornoxicam. Acta Derm Venereol; 2007;87(5):453-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma following administration of lornoxicam.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Piroxicam / analogs & derivatives. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced
  • [MeSH-minor] Adult. Back Pain / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721665.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 13T4O6VMAM / Piroxicam; ER09126G7A / lornoxicam
  •  go-up   go-down


3. Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, Caraglia M, Del Prete S: Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma. Clin Colorectal Cancer; 2007 Nov;6(10):728-30
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
  • Some conditions are predisposed to excessive lymphocyte responses, which can progress to a benign condition, ie, atypical cutaneous lymphoid hyperplasia (ACLH), or a malignant lymphoma.
  • Clinical diagnosis of drug-associated pseudolymphoma can be based on a temporal association between drug ingestion and lesion onset followed by resolution without recurrence after discontinuation of drug administration.
  • Herein, we report the case of a 66-year-old man with advanced colon carcinoma with ACLH developed while receiving chemotherapy regimen with oxaliplatin/5-fluorouracil/leucovorin.
  • The authors postulate that chemotherapy can promote an aberrant immune response to an antigen that can be the drug itself or other self-antigens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy. Drug Eruptions / etiology. Lymphatic Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039427.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


Advertisement
4. Takeda H, Kaneko T, Harada K, Matsuzaki Y, Nakano H, Hanada K: Successful treatment of lymphadenosis benigna cutis with topical photodynamic therapy with delta-aminolevulinic acid. Dermatology; 2005;211(3):264-6
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of lymphadenosis benigna cutis with topical photodynamic therapy with delta-aminolevulinic acid.
  • BACKGROUND: Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (ALA) has been used for nonmelanoma skin cancers, including malignant cutaneous T-cell lymphomas.
  • Moreover, PDT has been tried for benign inflammatory or infectious skin lesions.
  • OBJECTIVE: To evaluate the effects of ALA-PDT on skin lesions of lymphadenosis benigna cutis (LABC).
  • PATIENTS AND METHODS: Two 16-year-old females with solitary and infiltrated nodules were treated 5 times with topical ALA-PDT.
  • CONCLUSION: The results confirm that topical ALA-PDT is an effective and safe modality for the treatment of LABC, and that such treatment may be cosmetically beneficial.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Pseudolymphoma / drug therapy. Skin Diseases / drug therapy
  • [MeSH-minor] Adolescent. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16205072.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


5. Jain M, Agarwal K, Langer S, Aggarwal M: Cytomorphology of a case of primary cutaneous B-cell lymphoma. Indian J Pathol Microbiol; 2007 Oct;50(4):877-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of a case of primary cutaneous B-cell lymphoma.
  • Primary cutaneous lymphoma designates a heterogenous group of disorders arising from skin T and B cells with no evidence of extra cutaneous disease at the time of diagnosis and six months thereafter.
  • We report the cytomorphological features of a case of primary cutaneous lymphoma, B cell type in a 60 year old female presenting with multiple large bosselated red coloured swellings all over the scalp.
  • On cytology a diagnosis of B-cell cutaneous lymphoid hyperplasia (B-CLH) was given, however cutaneous lymphoma could not be ruled out.
  • On biopsy and immuno-histochemistry a diagnosis of primary cutaneous lymphoma B cell type was made.
  • Patient was started on specific chemotherapy of lymphoma to which she responded completely.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Female. Humans. Immunohistochemistry. Middle Aged. Scalp / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306596.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Magro CM, Crowson AN, Kovatich AJ, Burns F: Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol; 2003 Feb;34(2):119-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells.
  • Certain systemic conditions predispose patients to excessive lymphocyte responses to immune-perturbing drugs, which may progress to malignant lymphoma.
  • Many pathologists and clinicians believe that differentiation of pseudolymphoma from cutaneous T cell lymphoma (CTCL) can be reliably made through phenotypic and molecular analysis.
  • We encountered 15 cases of atypical cutaneous T-cell lymphoid hyperplasia in the setting of drug therapy.
  • The lymphoid infiltrates showed reproducible CD7 and/or CD62 K deletion in concert with T cell clonality and variable CD30 positivity-findings similar to those of CTCL-but the rashes resolved or improved substantially after drug modulation.
  • We propose the term "drug-induced reversible lymphoid dyscrasia" to describe this entity.
  • [MeSH-major] Dermatitis / etiology. Pseudolymphoma / chemically induced. Pseudolymphoma / pathology. T-Lymphocytes / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12612879.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


7. Tsujino Y, Dekio S: Cutaneous lymphoid hyperplasia: report of a case in which oral administration of minocycline was effective. J Dermatol; 2000 Nov;27(11):753-4
Hazardous Substances Data Bank. MINOCYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphoid hyperplasia: report of a case in which oral administration of minocycline was effective.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Minocycline / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11138546.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; FYY3R43WGO / Minocycline
  •  go-up   go-down


8. Wang E, Stoecker M: Primary cutaneous giant cell plasmacytoma in an organ transplant recipient: a rare presentation of a posttransplant lymphoproliferative disorder. Am J Dermatopathol; 2010 Jul;32(5):479-85
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous giant cell plasmacytoma in an organ transplant recipient: a rare presentation of a posttransplant lymphoproliferative disorder.
  • Posttransplant lymphoproliferative disorder (PTLD) is comprised of a spectrum of lymphoid diseases, ranging from early lesions, such as plasmacytic hyperplasia, to monomorphic neoplasms, including plasmacytoma-like lesions.
  • Although PTLD may involve a variety of organs, primary cutaneous PTLD is rare.
  • We report a unique case of Epstein-Barr virus (EBV)-positive primary cutaneous giant cell plasmacytoma developed 5 years after renal/pancreatic transplant in a 55-year-old male patient.
  • A review of the literature identified additional 49 cases of primary cutaneous B-cell PTLD, including 18 cases of plasmacytoma-like lesions.
  • Primary cutaneous B-cell PTLD usually presents years after transplantation, has male preponderance, tends to occur on extremities, is frequently EBV-associated, and predicts a favorable clinical outcome.
  • Unlike PTLD in general, in which EBV-positive cases usually occur earlier than EBV-negative ones, the longer presentation interval in the cutaneous PTLD seems to be uncorrelated to EBV status.
  • Compared with other subtypes of cutaneous B-cell PTLD, plasmacytoma-like lesions have an increased male preponderance and tendency to present on the extremities.
  • Although the majority of cases have been treated with reduction of immunosuppression, antiviral therapy and/or local radiotherapy, and a few with chemotherapy, the best therapeutic intervention for primary cutaneous B-cell PTLD remains to be further investigated with the analysis of more reported cases and large clinical trials.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414094.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Breza TS Jr, Zheng P, Porcu P, Magro CM: Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol; 2006 Jul;33(7):522-8
Hazardous Substances Data Bank. Bupropion .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response.
  • INTRODUCTION: Drugs may be an important cause of atypical lymphocytic infiltration.
  • We report a patient who developed lymphocytoma cutis temporally associated with initiation of fluoxetine therapy that later went on to develop cutaneous marginal zone B-cell lymphoma.
  • The response of peripheral blood lymphocytes to fluoxetine and other drugs was examined in an attempt to ascertain the potential role for drugs in the propagation of these infiltrates.
  • MATERIALS AND METHODS: Routine light microscopic analysis and phenotypic studies were performed on tissue obtained from a skin biopsy.
  • RESULTS: An initial biopsy was consistent with lymphocytoma cutis.
  • Other tested drugs did not have a similar suppressive effect.
  • [MeSH-minor] Anticonvulsants / pharmacology. Bupropion / pharmacology. Cells, Cultured. Dose-Response Relationship, Drug. Humans. In Situ Hybridization. Lymphocyte Activation / drug effects. Male. Middle Aged. Pseudolymphoma / chemically induced. Pseudolymphoma / pathology. T-Lymphocytes / drug effects. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872479.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antidepressive Agents, Second-Generation; 01K63SUP8D / Fluoxetine; 01ZG3TPX31 / Bupropion
  •  go-up   go-down


10. Priem S, Munkelt K, Franz JK, Schneider U, Werner T, Burmester GR, Krause A: [Epidemiology and therapy of Lyme arthritis and other manifestations of Lyme borreliosis in Germany: results of a nation-wide survey]. Z Rheumatol; 2003 Oct;62(5):450-8
MedlinePlus Health Information. consumer health - Lyme Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology and therapy of Lyme arthritis and other manifestations of Lyme borreliosis in Germany: results of a nation-wide survey].
  • [Transliterated title] Epidemiologie und Therapie der Lyme-Arthritis und anderer Manifestationen der Lyme-Borreliose in Deutschland. Ergebnisse einer bundesweiten Arzteumfrage.
  • Moreover, standardization of diagnostic or therapeutic procedures does not exist.
  • Therefore, a Germany-wide questionnaire-based survey was conducted in order to achieve more epidemiological data and to obtain more information about the diagnostic and therapeutic approaches of general practitioners and specialists.
  • During the collection period from March 1, 1998 to February 28, 1999, patients with Lyme disease were reported and information was given about site of infection, diagnostic procedures, clinical symptoms, treatment, and outcome.
  • 189 patients (4.8%) with lymphadenosis cutis benigna and 100 patients (2.5%) with acrodermatitis chronica atrophicans were reported.
  • In less than 10% of the cases, not evaluated or recommended therapeutic procedures were performed.
  • Most of the physicians taking part in this survey follow treatment recommendations concerning choice of antibiotics and treatment durations.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Child. Child, Preschool. Cross-Sectional Studies. Female. Germany / epidemiology. Health Surveys. Humans. Incidence. Lyme Neuroborreliosis / diagnosis. Lyme Neuroborreliosis / drug therapy. Lyme Neuroborreliosis / epidemiology. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14579032.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift für Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


11. Braun RP, French LE, Feldmann R, Chavaz P, Saurat JH: Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules. Br J Dermatol; 2000 Aug;143(2):411-4
MedlinePlus Health Information. consumer health - Eyelid Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules.
  • We describe a 74-year-old woman who rapidly developed bilateral voluminous nodules on the upper eyelids, following 4 months' treatment for chalazion.
  • Histological and immunohistochemical findings were suggestive of cutaneous pseudolymphoma (CPL), and extensive screening for malignant lymphoma (ML) remained negative.
  • Cutaneous pseudolymphomas are inflammatory diseases that can simulate ML either clinically, histopathologically, or both.
  • They are a rare cause of nodules of the upper eyelids, usually characterized by a benign evolution, that can be secondary to ultraviolet sensitivity, adverse reactions to systemic medications and contact sensitization, among others.
  • In our case, epicutaneous patch tests were strongly positive for a series of allergens contained in the ophthalmological preparations used; therefore, they were suggestive that the patient had CPL, lymphomatoid contact dermatitis type.
  • In addition, the patient had been treated previously with several drugs, known to cause CPL and immune dysregulation.
  • Complete regression of the lesions required treatment with systemic steroids and chlorambucil.
  • [MeSH-major] Dermatitis, Allergic Contact / diagnosis. Eyelid Diseases / diagnosis. Pseudolymphoma / diagnosis
  • [MeSH-minor] Aged. Chalazion / drug therapy. Diagnosis, Differential. Female. Humans. Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2006 Sep;155(3):633-4 [16911299.001]
  • (PMID = 10951155.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


12. O'Neill J, Fien S, Zeitouni NC: ALA-PDT for the treatment of cutaneous pseudolymphoma: a case report. J Drugs Dermatol; 2010 Jun;9(6):688-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALA-PDT for the treatment of cutaneous pseudolymphoma: a case report.
  • Cutaneous pseudolymphoma (CPL) is a benign skin condition that may cause cosmetic disfigurement, severe itch and, albeit rarely, transformation to malignant lymphoma.
  • The usual treatment modalities for CPL have been associated with adverse effects including skin atrophy and scarring.
  • This article reports the case of a patient with CPL on the cheek, which was treated with 5-aminolevulinic acid photodynamic therapy (ALA-PDT).
  • Controlled trials and long-term monitoring are warranted to further explore this treatment modality for CPL.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Photochemotherapy. Photosensitizing Agents / administration & dosage. Pseudolymphoma / drug therapy. Skin Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645532.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


13. Dar NR, Shaheen, Mustafvi SA, Raza N: Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. J Coll Physicians Surg Pak; 2005 Aug;15(8):496-7
Hazardous Substances Data Bank. HYDROQUINONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma.
  • Cutaneous pseudolymphoma is an aggregate of mature or abnormal looking lymphocytes in the dermis, which clinically and /or histologically simulates lymphoma but has a benign course and outcome.
  • Systemic drugs, especially anti-epileptics, are an important cause of cutaneous pseudolymphomas.
  • Pseudolymphoma of the skin, secondary to topical drug application, is very rare.
  • We report a case of cutaneous pseudolymphoma induced by local application of 4% hydroquinone cream to melasma over the cheeks.
  • [MeSH-major] Hydroquinones / adverse effects. Melanosis / drug therapy. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202363.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Hydroquinones; 123-31-9 / hydroquinone
  •  go-up   go-down


14. Malphettes M, Oksenhendler E, Galicier L, Fieschi C: [Granulomatous disease in common variable immunodeficiency]. Rev Med Interne; 2008 Jan;29(1):28-32
Genetic Alliance. consumer health - Common Variable Immunodeficiency.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Repeated bacterial infections and/or autoimmune manifestations and/or benign lymphoproliferation (including follicular hyperplasia and/or granulomatous disease) are the hallmark of the disease.
  • This review aims at describing recent advances in the understanding and treatment of granulomatous disease in CVID.
  • Granulomas may be found in several organs in a single patient, and the main features are pulmonary, lymphoid, cutaneous, hepatic or splenic.
  • Treatment consists in immunoglobulins substitution, immunosuppressive agents (corticosteroids, cyclophosphamide) and anti-TNFalpha antibodies.
  • These treatments are difficult to manage in such immunocompromised patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054123.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulins; 0 / Immunologic Factors; 0 / Immunosuppressive Agents
  • [Number-of-references] 21
  •  go-up   go-down


15. McComb ME, Telang GH, Vonderheid EC: Secondary syphilis presenting as pseudolymphoma of the skin. J Am Acad Dermatol; 2003 Aug;49(2 Suppl Case Reports):S174-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary syphilis presenting as pseudolymphoma of the skin.
  • The papulonodular variant has only been described 11 times in the literature.
  • We describe a case of papulonodular secondary syphilis presenting as an atypical lymphoid hyperplasia suggestive of cutaneous lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Syphilis, Cutaneous / pathology
  • [MeSH-minor] Adult. Anti-Bacterial Agents. Biopsy, Needle. Diagnosis, Differential. Drug Therapy, Combination / administration & dosage. Follow-Up Studies. Humans. Immunohistochemistry. Male. Risk Assessment. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894114.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


16. Kim KJ, Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK: CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. Br J Dermatol; 2002 May;146(5):882-4
Hazardous Substances Data Bank. GOLD, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture.
  • Cases of pseudolymphoma induced by intradermal gold injection or gold piercing have previously been described.
  • Most of these cases showed the histopathological finding of B-lymphocyte predominant lymphocytoma cutis.
  • We describe a patient with gold acupuncture-induced T-cell-rich pseudolymphoma.
  • [MeSH-major] Acupuncture Therapy / adverse effects. Drug Eruptions / etiology. Gold / adverse effects. Pseudolymphoma / chemically induced. T-Lymphocyte Subsets / pathology

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000389.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 7440-57-5 / Gold
  •  go-up   go-down


17. Prais D, Straussberg R, Amir J, Nussinovitch M, Harel L: Treatment of anticonvulsant hypersensitivity syndrome with intravenous immunoglobulins and corticosteroids. J Child Neurol; 2006 May;21(5):380-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anticonvulsant hypersensitivity syndrome with intravenous immunoglobulins and corticosteroids.
  • Anticonvulsant hypersensitivity syndrome is a specific severe idiosyncratic reaction to the aromatic antiepileptic drugs.
  • The most frequent presenting symptoms are fever and rash, lymphadenopathy owing to lymphoid hyperplasia, hepatitis, and interstitial nephritis.
  • Early detection is crucial owing to the high mortality rate.
  • Although withdrawal of the offending drug is critical, the optimal treatment approach remains controversial.
  • Previous studies report a severe course and prolonged hospital stay for cutaneous drug-related reactions, including referral to a burn center, skin débridement, and allograft skin coverage.
  • The aim of the present report is to describe four adolescents with antiepileptic drug hypersensitivity syndrome who were treated with intravenous immunoglobulin and systemic corticosteroids.
  • Findings indicate that this regimen might be a promising treatment option in this patient population.
  • Larger, controlled trials are needed to reach a definitive conclusion.
  • [MeSH-major] Anticonvulsants / adverse effects. Drug Hypersensitivity / drug therapy. Glucocorticoids / therapeutic use. Immunoglobulins, Intravenous / therapeutic use. Immunologic Factors / therapeutic use. Methylprednisolone / therapeutic use
  • [MeSH-minor] Adolescent. Drug Therapy, Combination. Female. Humans. Infusions, Intravenous. Syndrome

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901442.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Glucocorticoids; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


18. Tomar S, Stoll HL, Grassi MA, Cheney R: Treatment of cutaneous pseudolymphoma with interferon alfa-2b. J Am Acad Dermatol; 2009 Jan;60(1):172-4
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of cutaneous pseudolymphoma with interferon alfa-2b.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Pseudolymphoma / drug therapy. Skin Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103377.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


19. Guis S, Schiano de Colella JM, Bonnet N, Andrac-Meyer L, Balandraud N, Mattei JP, Franck B, Roudier C, Roudier J, Berbis P: Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept. Eur J Dermatol; 2008 Jul-Aug;18(4):474-6
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Immunoglobulin G / adverse effects. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573737.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; OP401G7OJC / Etanercept
  •  go-up   go-down


20. Aydogan K, Karadogan SK, Adim SB, Tunali S: Borrelial lymphocytoma cutis successfully treated with intralesional interferon-alpha-2A. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):1030-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borrelial lymphocytoma cutis successfully treated with intralesional interferon-alpha-2A.
  • [MeSH-major] Borrelia Infections / drug therapy. Ear, External. Interferon-alpha / administration & dosage. Pseudolymphoma / drug therapy. Skin Diseases, Bacterial / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922975.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


21. El-Dars LD, Statham BN, Blackford S, Williams N: Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol; 2005 May;30(3):305-7
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocytoma cutis treated with topical tacrolimus.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Pseudolymphoma / drug therapy. Skin Diseases / drug therapy. Tacrolimus / therapeutic use
  • [MeSH-minor] Administration, Cutaneous. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807704.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


22. Mikasa K, Watanabe D, Kondo C, Tamada Y, Matsumoto Y: Topical 5-aminolevulinic acid-based photodynamic therapy for the treatment of a patient with cutaneous pseudolymphoma. J Am Acad Dermatol; 2005 Nov;53(5):911-2
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-aminolevulinic acid-based photodynamic therapy for the treatment of a patient with cutaneous pseudolymphoma.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Pseudolymphoma / drug therapy. Skin Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243162.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Wiesli P, Joos L, Galeazzi RL, Dummer R: Cutaneous pseudolymphoma associated with bromocriptine therapy. Clin Endocrinol (Oxf); 2000 Nov;53(5):656-7
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pseudolymphoma associated with bromocriptine therapy.
  • [MeSH-major] Bromocriptine / adverse effects. Drug Eruptions / etiology. Hormone Antagonists / adverse effects. Pseudolymphoma / chemically induced. Skin Diseases / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106930.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Hormone Antagonists; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down






Advertisement